121 related articles for article (PubMed ID: 37431189)
1. ITIH5, as a predictor of prognosis and immunotherapy response for P53-like bladder cancer, is related to cell proliferation and invasion.
Peng K; Ding D; Wang N; Du T; Wang L; Duan X
Mol Omics; 2023 Oct; 19(9):714-725. PubMed ID: 37431189
[TBL] [Abstract][Full Text] [Related]
2. The ECM Modulator ITIH5 Affects Cell Adhesion, Motility and Chemotherapeutic Response of Basal/Squamous-Like (BASQ) Bladder Cancer Cells.
Rose M; Noetzel E; Kistermann J; Eschenbruch J; Rushrush S; Gan L; Knüchel R; Gaisa NT; Dahl E
Cells; 2021 Apr; 10(5):. PubMed ID: 33924987
[TBL] [Abstract][Full Text] [Related]
3. ITIH5, a p53-responsive gene, inhibits the growth and metastasis of melanoma cells by downregulating the transcriptional activity of KLF4.
Liu J; Cao F; Li X; Zhang L; Liu Z; Li X; Lin J; Han C
Cell Death Dis; 2021 May; 12(5):438. PubMed ID: 33935281
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of ITIH5 promotes bladder cancer progression and predicts early relapse of pT1 high-grade urothelial tumours.
Rose M; Gaisa NT; Antony P; Fiedler D; Heidenreich A; Otto W; Denzinger S; Bertz S; Hartmann A; Karl A; Knüchel R; Dahl E
Carcinogenesis; 2014 Mar; 35(3):727-36. PubMed ID: 24265292
[TBL] [Abstract][Full Text] [Related]
5. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
Front Immunol; 2022; 13():965469. PubMed ID: 36090967
[TBL] [Abstract][Full Text] [Related]
6. The extracellular matrix protein ITIH5 is a novel prognostic marker in invasive node-negative breast cancer and its aberrant expression is caused by promoter hypermethylation.
Veeck J; Chorovicer M; Naami A; Breuer E; Zafrakas M; Bektas N; Dürst M; Kristiansen G; Wild PJ; Hartmann A; Knuechel R; Dahl E
Oncogene; 2008 Jan; 27(6):865-76. PubMed ID: 17653090
[TBL] [Abstract][Full Text] [Related]
7. ITIH5 mediates epigenetic reprogramming of breast cancer cells.
Rose M; Kloten V; Noetzel E; Gola L; Ehling J; Heide T; Meurer SK; Gaiko-Shcherbak A; Sechi AS; Huth S; Weiskirchen R; Klaas O; Antonopoulos W; Lin Q; Wagner W; Veeck J; Gremse F; Steitz J; Knüchel R; Dahl E
Mol Cancer; 2017 Feb; 16(1):44. PubMed ID: 28231808
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic inactivation of the novel candidate tumor suppressor gene ITIH5 in colon cancer predicts unfavorable overall survival in the CpG island methylator phenotype.
Kloten V; Rose M; Kaspar S; von Stillfried S; Knüchel R; Dahl E
Epigenetics; 2014 Sep; 9(9):1290-301. PubMed ID: 25093535
[TBL] [Abstract][Full Text] [Related]
9. Overexpression of MTHFD2 represents an inflamed tumor microenvironment and precisely predicts the molecular subtype and immunotherapy response of bladder cancer.
Shi X; Peng X; Chen Y; Shi Z; Yue C; Zuo L; Zhang L; Gao S
Front Immunol; 2023; 14():1326509. PubMed ID: 38130721
[TBL] [Abstract][Full Text] [Related]
10. Gene expression analysis combined with functional genomics approach identifies ITIH5 as tumor suppressor gene in cervical carcinogenesis.
Dittmann J; Ziegfeld A; Jansen L; Gajda M; Kloten V; Dahl E; Runnebaum IB; Dürst M; Backsch C
Mol Carcinog; 2017 Jun; 56(6):1578-1589. PubMed ID: 28059468
[TBL] [Abstract][Full Text] [Related]
11. Low expression of ITIH5 in adenocarcinoma of the lung is associated with unfavorable patients' outcome.
Dötsch MM; Kloten V; Schlensog M; Heide T; Braunschweig T; Veeck J; Petersen I; Knüchel R; Dahl E
Epigenetics; 2015; 10(10):903-12. PubMed ID: 26252352
[TBL] [Abstract][Full Text] [Related]
12. A Robust Hypoxia Risk Score Predicts the Clinical Outcomes and Tumor Microenvironment Immune Characters in Bladder Cancer.
Liu Z; Tang Q; Qi T; Othmane B; Yang Z; Chen J; Hu J; Zu X
Front Immunol; 2021; 12():725223. PubMed ID: 34484235
[TBL] [Abstract][Full Text] [Related]
13. Decreased ITIH5 expression is associated with poor prognosis in primary gastric cancer.
Mai C; Zhao JJ; Tang XF; Wang W; Pan K; Pan QZ; Zhang XF; Jiang SS; Zhao BW; Li YF; Xia JC; Zhou ZW
Med Oncol; 2014 Jul; 31(7):53. PubMed ID: 24913813
[TBL] [Abstract][Full Text] [Related]
14. FGFR3 mutation characterization identifies prognostic and immune-related gene signatures in bladder cancer.
Xu PH; Chen S; Wang Y; Jin S; Wang J; Ye D; Zhu X; Shen Y
Comput Biol Med; 2023 Aug; 162():106976. PubMed ID: 37301098
[TBL] [Abstract][Full Text] [Related]
15. Siglec15 shapes a non-inflamed tumor microenvironment and predicts the molecular subtype in bladder cancer.
Hu J; Yu A; Othmane B; Qiu D; Li H; Li C; Liu P; Ren W; Chen M; Gong G; Guo X; Zhang H; Chen J; Zu X
Theranostics; 2021; 11(7):3089-3108. PubMed ID: 33537076
[No Abstract] [Full Text] [Related]
16. Genome-wide in vivo RNAi screen identifies ITIH5 as a metastasis suppressor in pancreatic cancer.
Sasaki K; Kurahara H; Young ED; Natsugoe S; Ijichi A; Iwakuma T; Welch DR
Clin Exp Metastasis; 2017 Apr; 34(3-4):229-239. PubMed ID: 28289921
[TBL] [Abstract][Full Text] [Related]
17. Deciphering the immunological and prognostic features of bladder cancer through platinum-resistance-related genes analysis and identifying potential therapeutic target P4HB.
Xiong S; Li S; Zeng J; Nie J; Liu T; Liu X; Chen L; Fu B; Deng J; Xu S
Front Immunol; 2023; 14():1253586. PubMed ID: 37790935
[TBL] [Abstract][Full Text] [Related]
18. ITIH5 induces a shift in TGF-β superfamily signaling involving Endoglin and reduces risk for breast cancer metastasis and tumor death.
Rose M; Meurer SK; Kloten V; Weiskirchen R; Denecke B; Antonopoulos W; Deckert M; Knüchel R; Dahl E
Mol Carcinog; 2018 Feb; 57(2):167-181. PubMed ID: 28940371
[TBL] [Abstract][Full Text] [Related]
19. Identification of the role of MCM6 in bladder cancer prognosis, immunotherapy response, and in vitro experimental investigation using multi-omics analysis.
Wang J; Li X; Chen S; Cao J; Fan X; Wang H; Zhang X; Yang L
Life Sci; 2023 Dec; 335():122253. PubMed ID: 37951536
[TBL] [Abstract][Full Text] [Related]
20. A novel metabolic subtype with S100A7 high expression represents poor prognosis and immuno-suppressive tumor microenvironment in bladder cancer.
Cai Y; Cheng Y; Wang Z; Li L; Qian Z; Xia W; Yu W
BMC Cancer; 2023 Aug; 23(1):725. PubMed ID: 37543645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
